Kentucky hemp company warns federal crackdown could hit traditional CBD

Kentucky Cannabis Company says new federal hemp restrictions aimed at intoxicating cannabinoids could also wipe out full-spectrum CBD products. The warning comes as implementation dates near in November and December 2026, raising uncertainty for hemp manufacturers.

Why it matters: - Kentucky Cannabis Company says federal hemp rules aimed at intoxicating products could unintentionally eliminate traditional, non-intoxicating full-spectrum CBD. - The company argues the policy could punish the original hemp industry along with products made through chemical conversion after the 2018 Farm Bill. - The coming rules could reshape what hemp products can legally be manufactured and sold in the U.S.

What happened: - Kentucky Cannabis Company, founded in 2014 during Kentucky’s industrial hemp research program, is warning about federal hemp restrictions scheduled to take effect on November 12 and December 11, 2026. - Founder Bill Polyniak says lawmakers should separate naturally derived hemp cannabinoids from intoxicating hemp products built from chemically converted compounds. - The company released its warning from Midway, Kentucky, on October 29, 2026.

The details: - The Agricultural Act of 2014 authorized state agriculture departments and eligible research institutions to grow industrial hemp through pilot programs. - Kentucky Cannabis Company says it built cultivation, extraction, and cannabinoid manufacturing capabilities before chemically converted intoxicating cannabinoids became a major market. - The Agriculture Improvement Act of 2018 expanded hemp legalization to include derivatives, extracts, cannabinoids, and isomers while keeping the 0.3% delta-9 THC limit. - That definition opened a path for delta-8 THC and similar intoxicating hemp-derived products, often made through chemical conversion of CBD. - The FDA received 104 adverse-event reports involving delta-8 THC products between December 1, 2020, and February 28, 2022. - Of those reports, 55% involved medical intervention or hospital admission. - Reported effects included hallucinations, vomiting, anxiety, confusion, and loss of consciousness. - National poison control centers received 2,362 delta-8 THC exposure reports between January 2021 and February 2022, including reports involving children. - The FDA has also warned about potentially harmful chemical byproducts from some cannabinoid conversion methods and weak manufacturing controls. - Traditional full-spectrum hemp extracts can preserve naturally occurring cannabinoids such as CBD, CBDA, CBG, CBC, and trace THC. - Some intoxicating hemp products use isolated CBD as a starting material for chemical conversion into other cannabinoids. - The company says those two manufacturing paths raise different safety and regulatory questions. - Federal hemp-definition amendments enacted in 2025 and modified in September 2026 set two key implementation dates. - Some provisions excluding cannabinoids that cannot naturally be produced by the cannabis plant take effect November 12, 2026. - Broader restrictions begin December 11, 2026, including a limit that excludes finished hemp cannabinoid products containing more than 0.4 milligrams of combined total THC and certain similarly acting cannabinoids per container. - The limit applies to the entire container, not an individual serving. - Kentucky Cannabis Company says a traditional full-spectrum CBD oil with naturally occurring trace THC could exceed that threshold even if it is not intended as an intoxicating product. - A Congressional Research Service legal analysis dated October 28, 2026, said the FDA had not yet published the cannabinoid classification lists and container guidance required by the law.

Between the lines: - The dispute is less about hemp itself than about how regulators define and separate naturally occurring cannabinoids from chemically manufactured intoxicants. - Kentucky Cannabis Company is trying to position full-spectrum CBD as a legitimate agricultural product that should not be grouped with products marketed for intoxication. - The company’s argument is also a warning about regulatory overreach, because a container-level THC rule could capture products that are not designed to produce a high. - Bill Polyniak founded the company after his family’s experience navigating his son’s severe epilepsy shaped his interest in plant-derived cannabinoid formulations. - The company says its experience over more than a decade predates the commercial surge in chemically converted hemp intoxicants. - Polyniak said, "We built this industry around cannabinoids grown by the plant. We should not lose traditional full-spectrum CBD because others exploited the 2018 loophole."

What's next: - Kentucky Cannabis Company is urging policymakers to close the pathway for chemically converted intoxicants without banning traditional full-spectrum CBD. - The company wants clearer distinctions among naturally extracted hemp cannabinoids, isolated cannabinoids, and cannabinoids made through chemical conversion. - It also supports transparent manufacturing, accurate labeling, contaminant testing, and tighter rules for intoxicating products. - The company says regulators can target safety risks without imposing a blanket restriction that removes non-intoxicating full-spectrum extracts from the market. - With the December 11 deadline approaching, the issue now turns to how federal agencies interpret and enforce the new hemp limits.

The bottom line: - Kentucky Cannabis Company says the federal crackdown on intoxicating hemp needs a sharper carveout, or traditional CBD could get caught in the net.